Receptor News and Research

RSS

Prickly pear may pack a surprising punch against metabolic syndrome

This narrative review examines how Opuntia ficus-indica fruit, or prickly pear, may help target multiple features of metabolic syndrome through its fiber, betalains, polyphenols, carotenoids, and other bioactive compounds. The authors conclude that the fruit shows promising mechanistic and preclinical potential, but stronger human trials are still needed before firm clinical claims can be made.

6 Apr 2026

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.

2 Apr 2026

Celiac disease weakens gut microbes that digest fiber

Findings suggest that impaired fiber metabolism in celiac disease is due to microbial deficits, not just diet, emphasizing the need for targeted interventions.

2 Apr 2026

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).

From Novo Nordisk 2 Apr 2026

Highly potent opioid shows potential as therapy for pain and opioid use disorder

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder.

1 Apr 2026

Molecular switch in neurons found to limit the regrowth of damaged axonal fibers

Researchers from the Icahn School of Medicine at Mount Sinai have discovered a molecular switch in neurons that limits the regrowth of damaged axonal fibers.

1 Apr 2026

Study reveals molecular control of tooth root formation and growth

Tooth root development relies on precise coordination of cellular signals, yet the underlying mechanisms remain unclear. Researchers have uncovered how two proteins, Gli2 and Gli3, work together to control signaling and differentiation in dental progenitor cells.

1 Apr 2026

How could bisphenol A raise depression risk? Study identifies six key molecular targets

An integrative Translational Psychiatry study linked BPA exposure to major depressive disorder by identifying 571 shared targets and six core genes, with genetic, transcriptomic, docking, and mouse-model data supporting plausible mechanistic pathways. The strongest signals pointed to AKT1, SRC, PLCG2, and JAK3 as potential contributors, while EGFR appeared protective.

31 Mar 2026

How vitamin D in the first 1,000 days may shape lifelong health

This narrative review argues that vitamin D is clearly important for skeletal health during the first 1,000 days of life and may also shape immune, metabolic, and selected neurodevelopmental pathways during early development. However, the authors stress that human evidence for most non-skeletal outcomes remains heterogeneous, with benefits appearing most consistent in populations with baseline deficiency.

31 Mar 2026

New therapy reprograms immune cells to reduce asthma inflammation

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and Shenzhen University School of Medicine has provided the first proof-of-principle study demonstrating that targeting a receptor on the surface of anti-inflammatory regulatory T cells (Tregs) can restore their function and alleviate asthma in mice.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

Excessive RNA editing enzyme alters brain circuit formation in Down syndrome

A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute for Brain Development has for the first time identified a biological process that may help explain how the brain develops differently in people with Down syndrome.

31 Mar 2026

How gut imbalance may drive obesity, diabetes, and heart disease

A new review argues that gut dysbiosis is closely linked to metabolic dysfunction through intertwined effects on inflammation, oxidative stress, gut barrier integrity, microbial metabolites, and epigenetic regulation. It also highlights microbiome-targeted strategies such as high-fiber diets, probiotics, prebiotics, postbiotics, exercise, and fecal microbiota transplantation as promising ways to support metabolic health.

30 Mar 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Artemin identified as marker and target in feline osteoarthritis

By comparing osteoarthritis pain pathways known to be active in dogs and humans to those in cats with degenerative joint disease (DJD), researchers found that elevation of a particular molecule, artemin, could serve as a marker of disease (and possibly pain) as well as a potential therapeutic target.

30 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

NOX-1 identified as key molecular target to prolong ketamine's antidepressant effects

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers rapid relief, its antidepressant effects fade within a few weeks.

30 Mar 2026

Parasites trigger a gut-to-brain signal that cuts food intake during infection

Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.

29 Mar 2026

APOE4 alters brain immunity and cognition differently in females and males

APOE4 drove sex-specific changes in meningeal immunity, lymphatic drainage, brain lipids, neuroinflammation, and cognition in mouse models, with females showing greater inflammatory and cognitive vulnerability. Suppressing innate immunity improved some cognitive outcomes in female E4/E4 mice but worsened them in male E4/E4 mice, underscoring the need for sex-tailored approaches.

29 Mar 2026